Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2002-07-30
2008-07-22
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093210, C424S093710
Reexamination Certificate
active
07402307
ABSTRACT:
The invention provides a method for activating a T lymphocyte by contacting the T lymphocyte with a dendritic cell (DC) that presents a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DC may be pulsed with a TRT polypeptide or may comprise a recombinant polynucleotide encoding a TRT such as hTRT. The invention also provides DCs comprising a recombinant TRT polynucleotide. The methods and compositions of the invention are used in prevention and treatment of cancers and other cell proliferation diseases or conditions.
REFERENCES:
patent: 4839290 (1989-06-01), Kaieda et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5645986 (1997-07-01), West et al.
patent: 5648219 (1997-07-01), MacKay et al.
patent: 5656638 (1997-08-01), Gaeta et al.
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 5853719 (1998-12-01), Nair et al.
patent: 5858777 (1999-01-01), Villeponteau et al.
patent: 5866115 (1999-02-01), Kanz et al.
patent: 5871728 (1999-02-01), Thomson et al.
patent: 5874307 (1999-02-01), Ohno et al.
patent: 5917025 (1999-06-01), Collins
patent: 5962318 (1999-10-01), Rooney et al.
patent: 5962320 (1999-10-01), Robinson
patent: 5968506 (1999-10-01), Weinrich et al.
patent: 5972627 (1999-10-01), Galy
patent: 5981707 (1999-11-01), Harrington et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 6004807 (1999-12-01), Banchereau et al.
patent: 6008004 (1999-12-01), Olweus et al.
patent: 6010905 (2000-01-01), Cohen et al.
patent: 6015554 (2000-01-01), Galy
patent: 6017527 (2000-01-01), Maraskovsky et al.
patent: 6033669 (2000-03-01), Jondal
patent: 6077519 (2000-06-01), Storkus et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6093809 (2000-07-01), Cech et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6224870 (2001-05-01), Segal
patent: 6261836 (2001-07-01), Cech et al.
patent: 6277613 (2001-08-01), De Lange et al.
patent: 6306388 (2001-10-01), Nair et al.
patent: 6387701 (2002-05-01), Nair et al.
patent: 6440735 (2002-08-01), Gaeta
patent: 689672 (2000-02-01), None
patent: 1093381 (2003-08-01), None
patent: WO 93/20185 (1993-10-01), None
patent: WO 94/02156 (1994-02-01), None
patent: WO 94/21287 (1994-09-01), None
patent: WO 94/28113 (1994-12-01), None
patent: WO 95/34638 (1995-12-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO 96/23060 (1996-08-01), None
patent: WO 97/04802 (1997-02-01), None
patent: WO 97/07200 (1997-02-01), None
patent: WO 97/22349 (1997-06-01), None
patent: WO 97/24447 (1997-07-01), None
patent: WO 97/29182 (1997-08-01), None
patent: WO 97/29183 (1997-08-01), None
patent: WO 97/34472 (1997-09-01), None
patent: WO 97/40182 (1997-10-01), None
patent: WO 9741210 (1997-11-01), None
patent: WO 98/01538 (1998-01-01), None
patent: WO 98/07838 (1998-02-01), None
patent: WO 98/14592 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/15615 (1998-04-01), None
patent: WO 98/21343 (1998-05-01), None
patent: WO 98/23759 (1998-06-01), None
patent: WO 98/37181 (1998-08-01), None
patent: WO 98/46083 (1998-10-01), None
patent: WO 98/55597 (1998-12-01), None
patent: WO 98/59040 (1998-12-01), None
patent: WO 98/59046 (1998-12-01), None
patent: WO 99/01560 (1999-01-01), None
patent: WO 99/25812 (1999-05-01), None
patent: WO 99/50392 (1999-10-01), None
patent: WO 99/51255 (1999-10-01), None
patent: WO 99/63050 (1999-12-01), None
patent: WO 99/63945 (1999-12-01), None
patent: WO 00/02581 (2000-01-01), None
patent: WO 00/08191 (2000-02-01), None
patent: WO 00/15264 (2000-03-01), None
patent: WO 00/25813 (2000-05-01), None
patent: WO 00/28000 (2000-05-01), None
patent: WO 00/61766 (2000-10-01), None
patent: WO 00/73420 (2000-12-01), None
patent: WO 01/60391 (2001-08-01), None
patent: WO 02/094213 (2002-11-01), None
patent: WO 03/038047 (2003-05-01), None
Ulloa-Montoya et al, (Journal of Bioscience and Bioengineering, vol. 100, pp. 12-27.
Wang et al (Journal of Experimental Medicine, 2005, vol. 201, pp. 1603-1614).
Jian et al, Nature, 2002, vol. 418, pp. 41-49.
Reyes et al, Blood, 2001, vol. 98, pp. 2615-2625.
Banchereau, J., et al., “Dendritic Cells and the Control of Immunity”, Nature, 392:245-252 (1998).
Banchereau, J., et al., “Immunobiology of Dendritis Cells”, Annu. Rev. Immunol., 18:767-811 (2000).
Cong, YS., et al., “The Humand Telomerase Catalytic Subunit hTERT: Organization of the Gene and Characterization of the Promoter”,Human Molecular Genetics, 8(1):137-142 (1999).
Greaces, M., Is Telomerase Activity in Cancer Due to Selection of Stem Cells and Differentiation Arrest?, Trends Genet., 12(4):127-128 (1996).
Greenberg, R.A., et al., “Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation”,Oncogene, 18:1219-1226 (1999).
Greener, M., “Telmoerase: The Search for a Universal Cancer Vaccine”, Molecular Med. Today, 6:257 (2000).
Hart, D., “Dendritic Cells: Unique Leukocyte Populations Which Control the Primary Immune Response”, blood, 90(9):3245-3287 (1997).
Hsu, et al., “Vaccinatin of Patients With B-Cells Lymphoma Using Autologous Antigen-Pulsed Dendritic Cells”, Nature Med., 2:52-58 (1996).
Koch, et al., “Antigen Processing In Populations of Mature Murine Dendritic Cells Is Caused by Subsets of Incompletely Matured Cells”, J. Immunol., 155:93-100 (1995).
Linger, J., et al ., “Purification of Telmoerase from Euplotes Aediculatus: Requirement of a Primer 3′ Overhang”, Proc. Natl. Acad. Sci. USA, 93:10712-10717 (1996).
McArthur, et al., “Induction of Protective Anti-Tumor Immunity by Gene-Modified Dendritic Cells”, J. Immunother,m 21:41-47 (1996).
Meyerson, M., et al., “hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and During Immortalization”, Cell, 90:785-795 (1997).
Minev, B., et al., “Cytotoxic T Cell Immunity Against Telomerase Reverse Transcriptase In Humans”, PNAS, 97(9):4796-4801 (2000).
Nair, et al., “Regression of Tumors In Mice Vaccinated With Professional Antigen-Presenting Cells Pused With Tumor Extracts”, Int. J. Caner, 70:706-715 (1997).
Norrback, K., et al., “Telmoeres and Telomerase in Normal and Malignant Hearmatopoletc Cells”, Eur. J. Cancer, 33(5):774-780 (1997).
Romani, N., et al., “Proliferating Dendritic Cell Progenitors in Human Blood”, J. Exp. Med., 180:83-93 (1994).
Tuting, et al., “Genetically Modified Bone Marrow-Derived Dendritic Cells Expressing Tumor-Associated Viral Or Sell Antigens Induce”, Eur. J. Immunol., 27:2702-2707 (1997).
Vonderhelde, R., et al., “the Telomerase Catalytic Subunit is A Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes”, Immunity, 10:673-679 (1999).
Yasui, W., et al., “Expression of Telomerase Catalytic Component, Telomerase Reverse Transcriptase, in Human Gastric Carcinomas”, Jpn. J. Cancer Res., 89:1099-1103 (1998).
Young, et al., “Dendritic Cells as Adjuvants For Class I Major Histocompatibility Complex-Restricted Antitiumor Immunity”, J. Exp. Med., 183:7-11 (1996).
Broccoli et al., Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2, Nature Gen 17:231 (1997).
Brun et al., Proteins that bind to double-stranded regions of telometric DNA, Trends In Cells Biol 7:317 (1997).
Chong et al., A human telomeric protein, Science 270:1663 (1995).
Greener, Telomerase: the search for a universal cancer vaccine, Mol Med Today 6:257 (20000.
Harrington et al., A mammalian telomerase-associated protein, Science 275:973 (19970.
Heiser et al., Human dendritic cells transfected with renal tumor RNA stimulate polycinal T-cell responses against antigens expressed by primary and metastic tumors, Cancer Res 61:3388 (2001).
Kim et al., TIN2, a new regulator of telomere length in human cell, Nature Gen 23:45 (1999).
Morin G, Is telomerase a universal cancer target? J
Canella Karen A
Earp David J.
Geron Corporation
Mooi Leslie A.
LandOfFree
Method for identifying and killing cancer cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identifying and killing cancer cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying and killing cancer cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3966411